完成两剂BBIBP-CorV疫苗接种的成人接种单剂Ad26.COV2.S异源加强针对抗SARS-CoV-2感染的1/2期开放标签试验第28天结果
在泰国已完成两剂BBIBP-CorV基础免疫的健康成人中开展1/2期开放标签试验,按不同间隔接种单剂Ad26.COV2.S(5×10^10病毒颗粒)异源加强针。第28天未发生严重不良事件,两组抗Spike结合抗体和中和抗体均较基线大幅升高,T细胞干扰素-γ约升高10倍。
要点
- 第0-7天征集性局部和全身不良事件大多为轻度,第0-28天非征集性疫苗相关不良事件亦多为轻度,无严重不良事件。
- 第28天A1组抗Spike结合抗体较基线升高487倍,A2组升高146倍。
- 第28天针对祖先SARS-CoV-2的中和抗体A1组升高55倍、A2组升高37倍,两组T细胞干扰素-γ均约升高10倍。
核心结论
- 完成两剂BBIBP-CorV后接种单剂异源Ad26.COV2.S加强针耐受良好,两个间隔组第28天均诱导了稳健的体液和细胞介导免疫应答。
研究设计与样本
- 开放标签1/2期试验,在泰国已完成两剂BBIBP-CorV基础免疫的健康成人中开展。
- 参与者在第二剂BBIBP-CorV后90-240天(A1组,n=360)或45-75天(A2组,n=66)接种单剂Ad26.COV2.S(5×10^10病毒颗粒),评估28天安全性及免疫原性。
- 采用酶联免疫吸附试验检测针对SARS-CoV-2全长融合前Spike和抗核衣壳蛋白的结合IgG抗体,用假病毒中和试验和活病毒微量中和试验定量针对祖先SARS-CoV-2(Wuhan-Hu-1)及delta(B.1.617.2)和omicron(B.1.1.529/BA.1和BA.2)变异株的中和活性,用全血定量干扰素(IFN)-γ释放试验检测细胞介导免疫应答。
主要发现
- 第0-7天征集性局部和全身不良事件大多为轻度,第0-28天非征集性疫苗相关不良事件亦多为轻度,无严重不良事件。
- 第28天抗Spike结合抗体较基线分别升高487倍(A1组)和146倍(A2组)。
- 第28天针对祖先SARS-CoV-2的中和抗体分别升高55倍(A1组)和37倍(A2组)。
- 体液免疫应答对祖先SARS-CoV-2最强,其次为delta,再次为omicron BA.2和BA.1变异株。
- 两组T细胞产生的干扰素-γ均约升高10倍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The inactivated COVID-19 whole-virus vaccine BBIBP-CorV has been extensively used worldwide. Heterologous boosting after primary vaccination can induce higher immune responses against SARS-CoV-2 than homologous boosting. The safety and immunogenicity after 28 days of a single Ad26.COV2.S booster dose given at different intervals after 2 doses of BBIBP-CorV are presented. METHODS: This open-label phase 1/2 trial was conducted in healthy adults in Thailand who had completed 2-dose primary vaccination with BBIBP-CorV. Participants received a single booster dose of Ad26.COV2.S (5 × 1010 virus particles) 90-240 days (Group A1; n = 360) or 45-75 days (Group A2; n = 66) after the second BBIBP-CorV dose. Safety and immunogenicity were assessed over 28 days. Binding IgG antibodies to the full-length pre-fusion Spike and anti-nucleocapsid proteins of SARS-CoV-2 were measured by enzyme-linked immunosorbent assay. The SARS-CoV-2 pseudovirus neutralization assay and live virus microneutralization assay were used to quantify the neutralizing activity of antibodies against ancestral SARS-CoV-2 (Wuhan-Hu-1) and the delta (B.1.617.2) and omicron (B.1.1.529/BA.1 and BA.2) variants. The cell-mediated immune response was measured using a quantitative interferon (IFN)-γ release assay in whole blood. RESULTS: Solicited local and systemic adverse events (AEs) on days 0-7 were mostly mild, as were unsolicited vaccine-related AEs during days 0-28, with no serious AEs. On day 28, anti-Spike binding antibodies increased from baseline by 487- and 146-fold in Groups A1 and A2, and neutralizing antibodies against ancestral SARS-CoV-2 by 55- and 37-fold, respectively. Humoral responses were strongest against ancestral SARS-CoV-2, followed by the delta, then the omicron BA.2 and BA.1 variants. T-cell-produced interferon-γ increased approximately 10-fold in both groups. CONCLUSIONS: A single heterologous Ad26.COV2.S booster dose after two BBIBP-CorV doses was well tolerated and induced robust humoral and cell-mediated immune responses measured at day 28 in both interval groups. CLINICAL TRIALS REGISTRATION: NCT05109559.
引用
- Muangnoicharoen S, Wiangcharoen R, Nanthapisal S, et al. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial. Vaccine. 2023. PMID: 37344265. doi:10.1016/j.vaccine.2023.06.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。